Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Applied Genetics Technologies Corporation

Request full access

Biotechnology company conducting human clinical trials of aav-based gene therapies for the treatment of rare diseases

Alachua, United StatesFounded 1999Biotech & Life Sciences

About Applied Genetics Technologies Corporation

Applied Genetics Technologies Corporation (AGTC), established in 1999, operated as a clinical-stage biotechnology company focused on developing gene therapies for rare and debilitating diseases. The company was acquired by Syncona in the fourth quarter of 2022 and now operates as a portfolio company, with its stock no longer publicly traded. The acquisition was valued at approximately $23.5 million upfront, with potential for an additional $50 million based on future milestones.

AGTC's business model revolved around its proprietary gene therapy platform, which utilizes adeno-associated virus (AAV) vectors to deliver functional genes to correct genetic defects. The company's primary focus was on inherited retinal diseases with high unmet medical needs, such as X-linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM). Prior to its acquisition, AGTC's strategy involved advancing its product candidates through clinical trials to gain regulatory approval and eventual commercialization, generating revenue through partnerships, and potentially, future product sales. A significant collaboration was established with Biogen in 2015 to develop gene-based therapies for several ophthalmic diseases, which included a $124 million upfront payment to AGTC.

The company's lead product candidate is AGTC-501 (laruparetigene zosaparvovec), a gene therapy for XLRP, a genetic eye disease that causes progressive vision loss in males. This therapy is designed to deliver a full-length version of the RPGR gene to address both rod and cone photoreceptor damage. Post-acquisition, under Beacon Therapeutics (another Syncona company), AGTC-501 has continued to show promise. As of October 2024, 24-month data from the Phase 2 SKYLINE trial showed a 57% response rate in improving retinal sensitivity in the high-dose group, with a favorable safety profile. The therapy is advancing to late-stage trials, with the Phase 2/3 VISTA trial currently enrolling patients. AGTC also developed candidates for achromatopsia, with AGTC-401 for CNGB3 mutations showing some positive activity, while the program for CNGA3 mutations (AGTC-402) was discontinued due to lack of clinical improvement.

Sue Washer served as the President and CEO for 17 years, leading the company from a university spin-out to a publicly traded entity before its acquisition. Her background combines a biochemistry degree with an MBA from the University of Florida, bridging the gap between science and business from her time at Abbott Labs and Eli Lilly. She was instrumental in securing significant investments, navigating the company through clinical milestones, and negotiating key partnerships.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1999
Headquarters
Alachua, United States
Listing
IPO 2014
Sector
Biotech & Life Sciences

Applied Genetics Technologies Corporation in the Alachua ecosystem

Live from Dealroom

The Applied Genetics Technologies Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • MedImmune Ventures
  • Intersouth Partners
  • InterWest Partners
  • Skyline Ventures
  • SR One
  • Alta Partners
  • Alta Capital Partners
  • Osage University Partners
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States75%
🏳️ Democratic Republic of the Congo8.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Applied Genetics Technologies Corporation on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Applied Genetics Technologies Corporation on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.